Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

• Published in: Journal of clinical lipidology Vol. 13; no. 3; pp. 374 - 392
• Main Authors: Wilson, Don P., Jacobson, Terry A., Jones, Peter H., Koschinsky, Marlys L., McNeal, Catherine J., Nordestgaard, Børge G., Orringer, Carl E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2019
• Subjects: Atherosclerotic cardiovascular disease; Biomarker; Biomarkers - blood; Blood Chemical Analysis; Calcific valvular aortic disease; Cardiovascular risk; Coronary heart disease; Cut points; Humans; Hypolipidemic Agents - pharmacology; Lifestyle; Lipoprotein (a); Lipoprotein(a) - blood; Lp(a); Myocardial infarction; Practice Guidelines as Topic; Primary prevention; Scientific statement; Secondary prevention; Societies, Scientific; Stroke; Treatment; Myocardial infarction; Biomarker; Stroke; Atherosclerotic cardiovascular disease; Coronary heart disease; Lp(a); Treatment; Calcific valvular aortic disease; Primary prevention; Cardiovascular risk; Scientific statement; Secondary prevention; Lifestyle; Cut points; Lipoprotein (a)
• ISSN: 1933-2874; 1876-4789
• DOI: 10.1016/j.jacl.2019.04.010

Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp...